Join Us On Facebook.
Follow us on Twitter.
Clearview News Wire
Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Avastin (bevacizumab) gives best lung cancer survival rate
August 9, 2010
Last Updated: 2010-08-06 17:38:26 -0400 (Reuters Health)By Katie Reid
ZURICH (Reuters) - Roche's top-selling Avastin (bevacizumab) helps patients with advanced non-small cell lung cancer live longer than any other treatment, the Swiss drugmaker said on Friday, giving the drug a boost after a slew of setbacks.
A late-stage trial showed first-line Avastin-based therapy resulted in a median overall survival of 14.2 months -- a 3.9-month improvement over chemotherapy alone.
Avastin has had a grim time this year, falling at key hurdles in prostate and gastric cancer, and last month a U.S. panel called on officials to revoke its approval in advanced breast cancer.
Avastin, which is already approved for colon, lung, brain and kidney cancers, is tipped to become the world's biggest selling drug in 2014.
Tweet
Other Articles:
- February 3, 2012
- Senators urge Komen to reconsider funding decision
- February 1, 2012
- Eating fish tied to lower risk of colon polyps
- January 31, 2012
- Kids seek tans, use less sunscreen as they Age
- January 18, 2012
- FDA approves BTG's drug for cancer toxicity
- January 5, 2012
- Argentina's Fernandez undergoes cancer surgery
- December 20, 2011
- Vitamin D has mixed effects on cancer, broken bones